• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Neuroscience
  • A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6280 When Given in Multiple Ascending Oral Doses in Healthy Male and Healthy Female Subjects of Non-child Bearing Potential.

Disease
anxiety, schizophrenia
Drug Name
AZD6280
Generic Name
AZD6280
Sponsor
AstraZeneca
Drug Status
Discontinued
Phase
I
Start Date
Mar 10, 2008
Study Name
D0850C00002
Study Id
D0850C00002
ClinicalTrials.gov ID
NCT00681317
Recruiting Status
Closed
Protocol Status
Not Available
Report
Apr 29, 2009
  • D0850C00002.pdf (140 KB)

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013